LINC00908 attenuates LUAD tumorigenesis through DEAD-box helicase 54

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• Lung adenocarcinoma (LUAD) is a major cause of cancer mortality globally.
• Understanding the molecular mechanisms driving LUAD progression is crucial for developing effective treatments.

Purpose of the Study:

• To identify novel molecular players involved in LUAD pathogenesis.
• To elucidate the role of long non-coding RNAs (lncRNAs) in LUAD.
• To investigate the potential of targeting specific molecular axes for LUAD therapy.

Main Methods:

• Identification of differentially expressed lncRNAs in LUAD tissues.
• Screening of a nine-gene risk signature including DDX54.
• Experimental validation of gene expression and functional roles using in vitro and in vivo models.
• Analysis of the regulatory network involving RFX2, LINC00908, and DDX54.

Main Results:

• LINC00908 was found to be downregulated in LUAD and associated with a favorable prognosis.
• LINC00908 inhibits LUAD glycolysis by regulating DEAD-box helicase 54 (DDX54) expression.
• The transcription factor RFX2 positively regulates LINC00908 expression.
• The RFX2/LINC00908/DDX54 axis significantly impacts LUAD tumor growth, metastasis, apoptosis, and glycolysis.

Conclusions:

• The RFX2/LINC00908/DDX54 axis represents a novel regulatory pathway in lung adenocarcinoma.
• This axis plays a critical role in LUAD tumorigenesis and progression.
• Targeting this axis holds promise for developing precise diagnostic and therapeutic strategies for LUAD.